260 related articles for article (PubMed ID: 12644981)
1. Phase I studies of ZD1839 in patients with common solid tumors.
Lorusso PM
Semin Oncol; 2003 Feb; 30(1 Suppl 1):21-9. PubMed ID: 12644981
[TBL] [Abstract][Full Text] [Related]
2. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.
Herbst RS
Semin Oncol; 2003 Feb; 30(1 Suppl 1):30-8. PubMed ID: 12644982
[TBL] [Abstract][Full Text] [Related]
3. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
Baselga J; Rischin D; Ranson M; Calvert H; Raymond E; Kieback DG; Kaye SB; Gianni L; Harris A; Bjork T; Averbuch SD; Feyereislova A; Swaisland H; Rojo F; Albanell J
J Clin Oncol; 2002 Nov; 20(21):4292-302. PubMed ID: 12409327
[TBL] [Abstract][Full Text] [Related]
4. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
Herbst RS; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Baselga J; Rojo F; Hong WK; Swaisland H; Averbuch SD; Ochs J; LoRusso PM
J Clin Oncol; 2002 Sep; 20(18):3815-25. PubMed ID: 12228201
[TBL] [Abstract][Full Text] [Related]
5. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
Von Pawel J
Bull Cancer; 2004 May; 91(5):E70-6. PubMed ID: 15582898
[TBL] [Abstract][Full Text] [Related]
6. New directions for ZD1839 in the treatment of solid tumors.
Schiller JH
Semin Oncol; 2003 Feb; 30(1 Suppl 1):49-55. PubMed ID: 12644984
[TBL] [Abstract][Full Text] [Related]
7. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.
Ranson M; Hammond LA; Ferry D; Kris M; Tullo A; Murray PI; Miller V; Averbuch S; Ochs J; Morris C; Feyereislova A; Swaisland H; Rowinsky EK
J Clin Oncol; 2002 May; 20(9):2240-50. PubMed ID: 11980995
[TBL] [Abstract][Full Text] [Related]
8. Impact of ZD1839 on non-small cell lung cancer-related symptoms as measured by the functional assessment of cancer therapy-lung scale.
Cella D
Semin Oncol; 2003 Feb; 30(1 Suppl 1):39-48. PubMed ID: 12644983
[TBL] [Abstract][Full Text] [Related]
9. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Adis International Ltd
Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
[TBL] [Abstract][Full Text] [Related]
10. ZD1839 (Iressa): for more than just non-small cell lung cancer.
Ranson M
Oncologist; 2002; 7 Suppl 4():16-24. PubMed ID: 12202784
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor tyrosine kinase inhibitors: evolving role in the treatment of solid tumors.
Krozely P
Clin J Oncol Nurs; 2004 Apr; 8(2):163-8. PubMed ID: 15108418
[TBL] [Abstract][Full Text] [Related]
12. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.
LoRusso PM; Herbst RS; Rischin D; Ranson M; Calvert H; Raymond E; Kieback D; Kaye S; Gianni L; Harris A; Bjork T; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Feyereislova A; Heyes A; Averbuch SD; Ochs J; Baselga J
Clin Cancer Res; 2003 Jun; 9(6):2040-8. PubMed ID: 12796366
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
Smith J
Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
[TBL] [Abstract][Full Text] [Related]
14. Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors.
Yamamoto N; Horiike A; Fujisaka Y; Murakami H; Shimoyama T; Yamada Y; Tamura T
Cancer Chemother Pharmacol; 2008 Mar; 61(3):489-96. PubMed ID: 17483950
[TBL] [Abstract][Full Text] [Related]
15. Studies with ZD1839 in preclinical models.
Sirotnak FM
Semin Oncol; 2003 Feb; 30(1 Suppl 1):12-20. PubMed ID: 12644980
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors.
Zhao Q; Shentu J; Xu N; Zhou J; Yang G; Yao Y; Tan F; Liu D; Wang Y; Zhou J
Lung Cancer; 2011 Aug; 73(2):195-202. PubMed ID: 21144613
[TBL] [Abstract][Full Text] [Related]
17. HER-targeted tyrosine-kinase inhibitors.
Baselga J; Hammond LA
Oncology; 2002; 63 Suppl 1():6-16. PubMed ID: 12422050
[TBL] [Abstract][Full Text] [Related]
18. ZD1839 (Iressa): what's in it for the patient?
Natale RB; Zaretsky SL
Oncologist; 2002; 7 Suppl 4():25-30. PubMed ID: 12202785
[TBL] [Abstract][Full Text] [Related]
19. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Vokes EE; Chu E
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
[TBL] [Abstract][Full Text] [Related]
20. Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy.
Wolf M; Swaisland H; Averbuch S
Clin Cancer Res; 2004 Jul; 10(14):4607-13. PubMed ID: 15269131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]